Validation of quality indicators for radical prostatectomy

International Journal of Cancer

Volumn 123, Issue 11, 2008, Pages 2651-2657

  Chan, Ellen O M ^a   Groome, Patti A ^a   Siemens, D Robert ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Construct validity; Prostatic neoplasms; Quality indicators; Surgery

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CANCER DIAGNOSIS; CANCER PATIENT; CONSTRUCT VALIDITY; CONTROLLED STUDY; FEASIBILITY STUDY; HEALTH CARE QUALITY; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

ACUTE DISEASE; AGED; BLOOD TRANSFUSION; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY INDICATORS, HEALTH CARE; REPRODUCIBILITY OF RESULTS;

EID: 57349085004     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23782     Document Type: Article

References (74)

1. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2006. Toronto: Canadian Cancer Society/National Cancer Institute of Canada, 2006.
2. Walsh PC, Retik AB, Vaughan E, Darracott E, Jr, Wein AJ, eds. Campbell's urology, 7th edn., vol. 1. Philadelphia: W.B. Saunders Company, 1998.
3. Goldenberg SL, Ramsey EW, Jewett MA. Prostate cancer: 6. surgical treatment of localized disease. CMAJ 1998;159:1265-71.
4. US National Institutes of Health. Prostate cancer treatment: health professional edition. Bethesda, MD: National Cancer Institute, US National Institutes of Health [updated 2007 Mar 14, cited 2007 Jun 6]. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/prostate/healthprofessional.
5. Linton KD, Hamdy FC. Early diagnosis and surgical management of prostate cancer. Cancer Treat Rev 2003;29:151-60.
6. Nam RK, Jewett MA, Krahn MD. Prostate cancer: 2. natural history. CMAJ 1998;159:685-91.
7. Gagliardi AR, Fleshner N, Langer B, Stern H, Brown AD. Development of prostate cancer quality indicators: a modified Delphi approach. Can J Urol 2005;12:2808-15.
8. Chong CC, Austen L, Kneebone A, Lalak A, Jalaludin B. Patterns of practice in the management of prostate cancer: results from multidisciplinary surveys of clinicians in Australia and New Zealand in 1995 and 2000. BJU Int 2006;97:975-80.
9. Morris CR, Snipes KP, Schlag R, Wright WE. Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States). Cancer Causes Control 1999;10:503-11.
10. Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH, Schroder FH. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 2006;50:475-82.
11. Bauvin E, Soulie M, Menegoz F, Mace-Lesec'h J, Buemi A, Velten M, Villers A, Grosclaude P. Medical and non-medical determinants of prostate cancer management: a population-based study. Eur J Cancer 2003;39:2364-71.
12. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The prostate patient outcomes research team. JAMA 1993; 269:2633-6.
13. Iscoe NA, To T, Gort E, Tran M. Cancer surgery in Ontario. Toronto: Institute for Clinical Evaluative Sciences, 1997.
14. Wilt TJ, Cowper DC, Gammack JK, Going DR, Nugent S, Borowsky SJ. An evaluation of radical prostatectomy at Veteran's Affairs Medical Centers: time trends and geographic variation in utilization and outcomes. Med Care 1999;37:1046-56.
15. Wennberg J, Gittelsohn A. Variations in medical care among small areas. Sci Am 1982;246:120-34.
16. Ellison LM, Trock BJ, Poe NR, Partin AW. The effect of hospital volume on cancer control after radical prostatectomy. J Urol 2005;173:2094-8.
17. Litwin MS, Steinberg M, Malin J, Naitoh J, McGuigan KA, Steinfeld R, Adams J, Brook RH. Prostate cancer patient outcomes and choice of providers: development of an infrastructure for quality assessment. Santa Monica, CA: RAND, 2000.
18. Spencer BA, Steinberg M, Malin J, Adams J, Litwin MS. Quality-of-care indicators for early-stage prostate cancer. J Clin Oncol 2003;21:1928-36.
19. Miller DC, Montie JE, Wei JT. Measuring the quality of care for localized prostate cancer. J Urol 2005;174:425-31.
20. Cancer Quality Council of Ontario. Strengthening the quality of cancer services in ontario. Toronto: Canadian Healthcare Association Press, 2003.
21. Miller DC, Litwin MS, Sanda MG, Montie JE, Dunn RL, Resh J, Sandler H, Wei JT. Use of quality indicators to evaluate the care of patients with localized prostate carcinoma. Cancer 2003;97:1428-35.
22. Krupski TL, Bergman J, Kwan L, Litwin MS. Quality of prostate carcinoma care in a statewide public assistance program. Cancer 2005;104:985-92.
23. Miller DC, Spencer BA, Ritchey J, Stewart AK, Dunn RL, Sandler HM, Wei JT, Litwin MS. Treatment choice and quality of care for men with localized prostate cancer. Med Care 2007;45:401-9.
24. McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires, 2nd edn. New York: Oxford University Press, 1996.
25. Kane RL, ed. Understanding health care outcomes research. Gaithersburg, MD: Aspen Publishers, 1997.
26. Begg CB, Riedel ER, Bach PB, Kattan MW, Schrag D, Warren JL, Scardino PT. Variations in morbidity after radical prostatectomy. N Engl J Med 2002;346:1138-44.
27. Nuttall M, van der MJ, Phillips N, Sharpin C, Gillatt D, McIntosh G, Emberton M. A systematic review and critique of the literature relating hospital or surgeon volume to health outcomes for 3 urological cancer procedures. J Urol 2004;172:t-52.
28. Ellison LM, Heaney JA, Birkmeyer JD. The effect of hospital volume on mortality and resource use after radical prostatectomy. J Urol 2000;163:867-9.
29. Hu JC, Gold KF, Pashos CL, Mehta SS, Litwin MS. Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol 2003;21:401-5.
30. Siemens DR, Schulze KM, Mackillop WJ, Brundage MD, Groome PA. A population-based study of the waiting times for prostatectomy in Ontario. Can J Urol 2005;12:2568-74.
31. Boulos DL, Groome PA, Brundage MD, Siemens DR, Mackillop WJ, Heaton JP, Schulze KM, Rohland SL. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent. Cancer 2006;106:1804-14.
32. Commission on Professional and Hospital Activities. The International classification of diseases; 9th revision, clinical modification; ICD-9-CM. Ann Arbor, MI, 1978.
33. MedQuest Software [computer program]. Version 32. Baltimore: US Centers for Medicare & Medicaid Services, 1998.
34. Statistics Canada HD. Canadian classification of diagnostic, therapeutic, and surgical procedures. Ottawa: Minister of Supply and Services Canada, 1986.
35. Eastham JA, Kattan MW, Rogers E, Goad JR, Ohori M, Boone TB, Scardino PT. Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996;156:1707-13.
36. Alibhai SM, Leach M, Tomlinson G, Krahn MD, Fleshner N, Holowaty E, Naglie G. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst 2005;97:1525-32.
37. US National Institutes of Health. Prostate cancer treatment: health professional edition. Bethesda, MD: National Cancer Institute, US National Institutes of Health [updated 2006 May 25, cited 2006 Jun 5]. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/prostate/healthprofessional/ allpages.
38. Kantoff PW, Carroll PR, D'Amico AV, eds. Prostate Cancer: Principles & Practice, 1st edn. Philadelphia: Lippincott, 2002.
39. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968;16:622-6.
40. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF. Rating chronic medical illness burden in geropsychiatric practice and research: application of cumulative illness rating scale. Psychiatry Res 1992;41:237-48.
41. Ansari MZ, Ackland MJ, Jolley DJ, Carson N, McDonald IG. Interhospital comparison of mortality rates. Int J Qual Health Care 1999;11:29-35.
42. Ansari MZ, Costello AJ, Jolley DJ, Ackland MJ, Carson N, McDonald IG. Adverse events after prostatectomy in Victorian public hospitals. Aust N Z J Surg 1998;68:830-6.
43. Fleshner N. Defining high-risk prostate cancer: current status. Can J Urol 2005;12 (Suppl 1):14-7.
44. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Coleman CN. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999;17:168-72.
45. D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M, Art M, Tomaszewski JE, Wein A. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 2000;55:572-7.
46. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003;21:2163-72.
47. Doherty AP, Bower M, Smith GL, Miano R, Mannion EM, Mitchell H, Christmas TJ. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer 2000;83:1432-6.
48. SAS (Statitiscal Analysis Software) [computer program]. Version 8.2. Cary, NC: SAS Institute, 2000.
49. SAS v9 Documentation. Cary, NC: SAS Institute, Inc The FREQ Procedure: Cochran-Armitage Test for Trend [updated 2003, cited 2007 Mar 18]. Available from: http://support.sas.com/91doc/getDoc/procstat.hlp/freq_sect24.htm.
50. SAS v9 Documentation. Cary, NC: SAS Institute, Inc The NPAR1-WAY Procedure: Exact Tests [updated 2003, cited 2007 Mar 18]. Available from: http://support.sas.com/91doc/getDoc/statug.hlp/npar1way_sect19. htm#stat_npar1way_np1exmc1.
51. Rothman KJ, Greenland S. Modern epidemiology, 2nd edn. Philadelphia: Lippincott-Raven, 1998.
52. Hu JC, Gold KF, Pashos CL, Mehta SS, Litwin MS. Temporal trends in radical prostatectomy complications from 1991 to 1998. J Urol 2003;169:1443-8.
53. British Columbia Cancer Agency. Cancer management guidelines: prostate. Vancouver, BC: British Columbia Cancer Agency [updated 2006 Jun 30, cited 2007 Jun 6]. Available from: http://www.bccancer.bc.ca/HPI/ CancerManagementGuidelines/Genitourinary/Prostate/default.htm.
54. Yao SL, Lu-Yao GL. Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay. J Natl Cancer Inst 1999;91:1950-6.
55. Bianco FJ, Jr, Riedel ER, Begg CB, Kattan MW, Scardino PT. Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol 2005;173:2099-103.
56. Joudi FN, Konety BR. The impact of provider volume on outcomes from urological cancer therapy. J Urol 2005;174:432-8.
57. Holowaty EJ, Dale D. The hospital only project. Health Rep 1993;5:91-5.
58. Holowaty EJ, Moravan V, Lee G, Chong N, Dale D. A reabstraction study to estimate the completeness and accuracy of data elements in the Ontario Cancer Registry. Cancer Care Ontario Report 1996.
59. Canadian Institute for Health Information. Data quality documentation: discharge abstract database 2001-2002. Ottawa; CIHI, 2003.
60. Alivizatos G, Skolarikos A. Incontinence and erectile dysfunction following radical prostatectomy: a review. Sci World J 2005;5:747-58.
61. Robinson JW, Dufour MS, Fung TS. Erectile functioning of men treated for prostate carcinoma. Cancer 1997;79:538-44.
62. Shekarriz B, Upadhyay J, Wood DP. Intraoperative, perioperative, and long-term complications of radical prostatectomy. Urologic Clin North Am 2001;28:639-53.
63. Power and Precision [computer program]. Version 2.1. Englewood, NJ: Biostat, 2001.
64. Cancer Care Ontario. Cancer Quality Council of Ontario. Cancer Service Quality Index 2007 [Internet]. Toronto: Cancer Care Ontario [updated 2007, cited 2007 Jun 10]. Available from: http://www.cancercare.on.ca/qualityindex2007/.
65. Dash A, Dunn RL, Resh J, Wei JT, Montie JE, Sanda MG. Patient, surgeon, and treatment characteristics associated with homologous blood transfusion requirement during radical retropubic prostatectomy: multivariate nomogram to assist patient counseling. Urology 2004;64:117-22.
66. Van Poppel H, Collette L, Kirkali Z, Brausi M, Hoekstra W, Newling DW, Decoster M. Quality control of radical prostatectomy: a feasibility study. Eur J Cancer 2001;37:884-91.
67. Van Poppel H, Boulanger SF, Joniau S. Quality assurance issues in radical prostatectomy. Eur J Surg Oncol 2005;31:650-5.
68. Klein EA, Grass JA, Calabrese DA, Kay RA, Sargeant W, O'Hara JF. Maintaining quality of care and patient satisfaction with radical prostatectomy in the era of cost containment. Urology 1996;48:269-76.
69. Gardner TA, Bissonette EA, Petroni GR, McClain R, Sokoloff MH, Theodorescu D. Surgical and postoperative factors affecting length of hospital stay after radical prostatectomy. Cancer 2000;89:424-30.
70. Montorsi F, Briganti A, Salonia A, Rigatti P, Burnett AL. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol 2004;45:123-33.
71. Meuleman EJ, Mulders PF. Erectile function after radical prostatectomy: a review. Eur Urol 2003;43:95-101.
72. Dubbelman YD, Dohle GR, Schroder FH. Sexual function before and after radical retropubic prostatectomy: a systematic review of prognostic indicators for a successful outcome. Eur Urol 2006;50:711-8.
73. Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999;162:433-8.
74. Salomon L, Levrel O, de la TA, Anastasiadis AG, Saint F, Zaki S, Vordos D, Cicco A, Olsson LE, Hoznek A, Chopin D, Abbou CC. Radical prostatectomy by the retropubic, perineal and laparoscopic approach: 12 years of experience in one center. Eur Urol 2002;42:104-10.